Trials / Terminated
TerminatedNCT04803123
Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL
Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in Relapsed or Refractory Adult B-cell Acute Lymphoblastic Leukemia
- Status
- Terminated
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Dorothy Sipkins, MD, PhD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will provide an evaluation of biologic markers of leukemia cell response following a single dose of copanlisib prior to any salvage induction therapy in a projected cohort of 10 relapsed/refractory B-ALL patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Copanlisib | Patients must receive at least one dose of copanlisib prior to standard therapy to be evaluable. |
Timeline
- Start date
- 2021-06-21
- Primary completion
- 2023-04-03
- Completion
- 2023-04-26
- First posted
- 2021-03-17
- Last updated
- 2023-12-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04803123. Inclusion in this directory is not an endorsement.